Chronic lymphocytic leukemia (CLL) and prolymphocytic leukemia (PLL) are types of blood cancer. They develop in types of white blood cells called B cells or T cells, or the precursors to these cells.

Trying to break from the decade-old practice of using BTK inhibitors indefinitely to treat blood cancer, AstraZeneca has positive data suggesting two fixed-duration combinations containing its ...

A diagnosis of chronic lymphocytic leukemia (CLL) can be overwhelming, but advances in cancer research, including targeted therapies, have paved the way for more precise treatments. Donald Trump ...

A review of machine learning (ML) models developed to support the management of chronic lymphocytic leukemia (CLL) have demonstrated positive outcomes, including accurate diagnosis and improved work ...

Acalabrutinib (Calquence) yielded high efficacy and a manageable safety profile for the treatment of chronic lymphocytic leukemia (CLL) in older and/or frail patients, according to findings from the ...

New EORTC guidelines establish meaningful change thresholds for symptom burden, physical condition/fatigue, and worries/fears in R/R CLL or SLL patients. Thresholds help identify significant ...

Evaluating CR as a surrogate endpoint for PFS in R/R chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): A meta-analysis of randomized controlled trials (RCT). CR/CRi (vs non-CR/CRi) ...

Risk of invasive fungal infections in patients with chronic lymphocytic leukemia treated with Bruton tyrosine kinase inhibitors: A TriNetX-based retrospective cohort study from 2000-2025. Propensity ...